Evidence map›Paper›PMID 25516647›Full record

ReviewWorld journal of gastroenterology2014

Hepatitis B and human immunodeficiency virus co-infection.

Bao-Chau Phung, Philippe Sogni, Odile Launay

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. The As and Bs of HIV and Hepatitis Co-Infection.Tropical medicine and infectious disease · 2019
    Review
  14. Article
  15. [Use of hepatitis B AS04C adjuvanted vaccine in HIV patients].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2018
    Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bao-Chau PhungBao-Chau Phung, Philippe Sogni, Odile Launay, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France.
Philippe SogniBao-Chau Phung, Philippe Sogni, Odile Launay, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France.
Odile LaunayBao-Chau Phung, Philippe Sogni, Odile Launay, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B and human immunodeficiency virus (HBV and HIV) infection share transmission patterns and risk factors, which explains high prevalence of chronic HBV infection in HIV infected patients. The natural course of HBV disease is altered by the HIV infection with less chance to clear acute HBV infection, faster progression to cirrhosis and higher risk of liver-related death in HIV-HBV co-infected patients than in HBV mono-infected ones. HIV infected patients with chronic hepatitis B should be counseled for liver damage and surveillance of chronic hepatitis B should be performed to screen early hepatocellular carcinoma. Noninvasive tools are now available to evaluate liver fibrosis. Isolated hepatitis B core antibodies (anti-HBc) are a good predictive marker of occult HBV infection. Still the prevalence and significance of occult HBV infection is controversial, but its screening may be important in the management of antiretroviral therapy. Vaccination against HBV infection is recommended in non-immune HIV patients. The optimal treatment for almost all HIV-HBV co-infected patients should contain tenofovir plus lamivudine or emtricitabine and treatment should not be stopped to avoid HBV reactivation. Long term tenofovir therapy may lead to significant decline in hepatitis B surface Antigen. The emergence of resistant HBV strains may compromise the HBV therapy and vaccine therapy.

Indexed as

CoinfectionHepatitis B, ChronicHIV InfectionsAnti-HIV AgentsAntiviral AgentsDrug Resistance, ViralDrug Therapy, CombinationHepatitis B VaccinesHumansPrevalenceTime FactorsTreatment OutcomeVaccinationAnti-HIV AgentsAntiviral AgentsHepatitis B VaccinesChronic hepatitis BHuman immunodeficiency virusManagementOccult hepatitisTreatment

Identifiers

PMID25516647
PMCPMC4265594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.